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OBJECTIVE—Most animals experience fasting–feeding cycles
throughout their lives. It is well known that the liver plays a central
role in regulating glycogen metabolism. However, how hepatic
glycogenesis is coordinated with the fasting–feeding cycle to con-
trol postprandial glucose homeostasis remains largely unknown.
This study determines the molecular mechanism underlying the
coupling of hepatic glycogenesis with the fasting–feeding cycle.
RESEARCH DESIGN AND METHODS—Through a series of
molecular, cellular, and animal studies, we investigated how
PPP1R3G, a glycogen-targeting regulatory subunit of protein
phosphatase 1 (PP1), is implicated in regulating hepatic glyco-
genesis and glucose homeostasis in a manner tightly orchestrated
with the fasting–feeding cycle.
RESULTS—PPP1R3G in the liver is upregulated during fasting
and downregulated after feeding. PPP1R3G associates with
glycogen pellet, interacts with the catalytic subunit of PP1, and
regulates glycogen synthase (GS) activity. Fasting glucose level is
reduced when PPP1R3G is overexpressed in the liver. Hepatic
knockdown of PPP1R3G reduces postprandial elevation of GS
activity, decreases postprandial accumulation of liver glycogen,
and decelerates postprandial clearance of blood glucose. Other
glycogen-targeting regulatory subunits of PP1, such as PPP1R3B,
PPP1R3C, and PPP1R3D, are downregulated by fasting and in-
creased by feeding in the liver.
CONCLUSIONS—We propose that the opposite expression
pattern of PPP1R3G versus other PP1 regulatory subunits comprise
an intricate regulatory machinery to control hepatic glycogenesis
during the fasting–feeding cycle. Because of its unique expression
pattern, PPP1R3G plays a major role to control postprandial glu-
cose homeostasis during the fasting–feeding transition via its reg-
ulation on liver glycogenesis. Diabetes 60:1435–1445, 2011
T
he blood glucose level ﬂuctuates with the fasting–
feeding cycle in most animals. On feeding, the
increase in postprandial blood glucose is mainly
reduced by increased glucose uptake in periph-
eral tissues, such as liver and skeletal muscles. This process
is regulated by changes in the insulin/glucagon ratio, by
portal signals, and by the blood glucose concentra-
tion itself (1–3). The liver, as a glucose sensor, actively
contributes to the control of postprandial blood glucose
homeostasis (4). In particular, the liver takes up approxi-
mately one-third of the oral glucose load in the animal (5).
In the liver, glycogen metabolism is regulated in a complex
manner to maintain postprandial blood glucose homeo-
stasis (2,6–11). In brief, two critical enzymes are directly
involved in glycogen metabolism, glycogen synthase (GS)
for glycogenesis and glycogen phosphorylase (GP) for
glycogenolysis. The activities of GS and GP are regulated
by phosphorylation/dephosphorylation events, but in op-
posing directions. GS is inhibited by phosphorylation at
multiple sites mediated by protein kinases, such as protein
kinase A and glycogen synthase kinase 3 (GSK3), and ac-
tivated by dephosphorylation via glycogen synthase phos-
phatase (GSP). On the other hand, GP is activated by
phosphorylation at a single residue near the N-terminus by
phosphorylase kinase and inhibited by dephosphorylation
by protein phosphatase 1 (PP1). A postprandial increase
in blood glucose results in an elevated intracellular con-
centration of glucose that binds activated GP (GPa) and
promotes its dephosphorylation and inactivation, thus re-
leasing the allosteric inhibitory effect of GPa on GSP (8).
On the other hand, glucose-6-phosphate (G6P) produced
from glucose is an allosteric activator of GS, and the
potency of G6P as an activator increases as GS is de-
phosphorylated by GSP (7). In addition, the postprandial
increase of insulin stimulates GS by reducing its phos-
phorylation and inactivation by GSK3, at least in muscle
(12). Collectively, these events converge to activate GS
and inhibit GP on feeding, resulting in accumulation of liver
glycogen after a meal.
PP1 plays a critical role in glucose metabolism because
of its regulatory effects on glycogen metabolizing enzymes,
including GS, GP, and GP kinase (9,11). The PP1 holoen-
zyme is composed of a catalytic subunit (PP1c) and a reg-
ulatory subunit (11). In regulating glycogen metabolism,
PP1c is anchored to the glycogen particles by a group of
glycogen-targeting regulatory subunits (G subunits) that
modulate the activities of the glycogen metabolizing enzymes
through PP1-mediated dephosphorylation. According to
the GenBank database, there are seven genes encoding
G subunits (PPP1R3A to PPP1R3G), all of which possess a
PP1-binding domain and a glycogen-binding domain (11,13).
The intricate regulation of glycogen metabolism by
G subunits has been established over the past 25 years by
extensive and detailed analysis of two of these proteins,
GM/PPP1R3A and GL/PPP1R3B, which are expressed rel-
atively speciﬁcally in skeletal muscle and the liver, respec-
tively, in rodents. The importance of these two proteins
in regulating glycogen metabolism was ﬁrmly established
by studies with mice that had a deletion of GM/PPP1R3A
(14,15), or mice with expression of a deregulated form of
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ORIGINAL ARTICLEFIG. 1. PPP1R3G is regulated in the fasting–feeding cycle. A: Male C57BL/6 J mice at 8 weeks of age were killed in the constant feeding state or
after 6-h (from 0:00 to 6:00 A.M.) or 12-h fasting (from 6:00 P.M. to 6:00 A.M. the next day). Liver PPP1R3G and FGF21 mRNA levels were measured
by RT-qPCR (n=4 mice/group). Fold change of each gene compared with actin is shown as mean 6 SD. *P < 0.05, **P < 0.01, and ***P < 0.001 as
compared with the feeding group. B: Liver protein samples in A were used in immunoblotting to detect protein levels of PPP1R3G and tubulin.
C: PPP1R3G mRNA levels in brain, white adipose tissue, and skeletal muscle in feeding or after 12-h fasting. D: Male C57BL/6 J mice at 8 weeks of
age were killed in the feeding state, after 12-h fasting, or after refeeding for the time as indicated. Liver PPP1R3G mRNA level was measured by
RT-qPCR (n=4 mice/group). Statistical analysis is done by comparing the refeeding group with the fasting group. *P < 0.05, **P < 0.01, and ***P <
0.001 as compared with the group of feeding for 12 h. E: Liver samples in D were used in immunoblotting with the antibodies as indicated (top).
Quantitation of the data is shown (bottom). **P < 0.01 between the groups as indicated. F: Primary hepatocytes isolated from overnight-fasted
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PTG/R5/PPP1R3C had reduced glycogen levels in several
tissues and became glucose intolerant and insulin resistant
as they aged (17). In contrast, little is known about the
physiologic function of other G subunits and the reason for
the plethora of genes encoding this group of proteins.
Furthermore, how G subunits are coordinated with the
fasting–feeding cycle to control postprandial glucose ho-
meostasis is largely unknown. In this study, we demonstrate
that PPP1R3G, a previously uncharacterized glycogen-
targeting regulatory subunit of PP1, is actively involved in
the control of blood glucose homeostasis by regulating
hepatic glycogenesis in a manner closely coordinated with
the fasting–feeding cycle.
RESEARCH DESIGN AND METHODS
Descriptions of the detailed protocols used in many assays of this study are
provided in the Supplementary Data.
Animal studies. All animal protocols were approved by the Institutional
Animal Care and Use Committee of the Institute for Nutritional Sciences,
Chinese Academy of Sciences. Male C57BL/6 J mice were from Shanghai
Laboratory Animal Co. Ltd.
Plasmids, cell culture, and transfection. The full-length mouse cDNA of
PPP1R3C, PPP1R3G, and PP1c was cloned from mouse liver by RT-PCR and
conﬁrmed by DNA sequencing. PPP1R3C, PPP1R3G, and PPP1R3G with de-
letion of putative glycogen binding domain PPP1R3G(DGB) (deletion of the
amino acid residues 225 to 247) were subcloned into the mammalian ex-
pression vector pRc/CMV with a Flag epitope tag added to the N-termini. PP1c
was cloned into the mammalian expression vector pCS2+MT with six Myc tags
at the N terminus. PPP1R3G was also cloned into the pGEX-4T1 vector to
generate glutathione-S-transferase (GST)-fused protein. PP1c was also cloned
into the pET-30a vector to generate His-fused protein. Cell culture and
transfection were as previously described (18).
Antibodies, immunoblotting, and coimmunoprecipitation. The antibodies
were purchased as follows: monoclonal anti-Flag antibody from Sigma-Aldrich
(St. Louis, MO); antibodies against Myc, tubulin from Santa Cruz Biotechnology
(Santa Cruz, CA); antibodies against PP1c and GS from Cell Signaling Tech-
nology (Boston, MA); antibody against phosphorylated GS at Ser641 from
Abcam (Boston, MA); Alexa Fluor 488 donkey anti-mouse IgG, Alexa Fluor 546
goat anti-mouse IgG, and Hoechst 33342 from Molecular Probes (Eugene, OR).
The polyclonal PPP1R3G antibody was generated by mouse immunization with
a GST-fused PPP1R3G protein. Immunoblotting and coimmunoprecipitation
assays were previously described (18).
Isolation of primary hepatocytes and adenovirus experiments. Isolation
ofprimaryhepatocytesandadenovirusinfectionwaspreviouslydescribed(19).
Flag-tagged PPP1R3G adenovirus was generated using the AdEasy Adenoviral
Vector System (Stratagene, La Jolla, CA) according to the manufacturer’si n -
structions. Adenoviruses with either scrambled sequence or short hairpin (sh)
RNA sequence speciﬁc for mouse PPP1R3G were generated using the BLOCK-iT
Adenoviral RNAi Expression System (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions.
Measurement of glycogen content. Cell glycogen content measurement was
performed as previously described (20). Liver glycogen content measurement
was described previously (21).
Analysis of newly synthesized glycogen using D-[3-
3H]glucose tracer.
Mice were fasted overnight and injected intraperitoneally with glucose (2 g/kg
body wt) containing a trace amount of D-[3-
3H]glucose (Perkin Elmer Life and
Analytical Sciences, Waltham, MA; speciﬁca c t i v i t y7 4 0G B q / m m o l )a t0 . 5mCi/g
body wt. One hour later, the mice were killed and liver glycogen was isolated
using an ethanol-based method (21). The glycogen precipitate was dissolved in
H2O, and an aliquot was used in scintillation counting.
GS activity and GP assays. GS activity assay was performed as previously
described (14,22). GP activity assay was previously described (14,23).
Statistical analysis. All data were analyzed by two-tailed Student t test.
RESULTS
PPP1R3G is regulated by the fasting–feeding cycle.
To gain a global view of genes regulated by fasting in the
liver, we examined genes of the whole mouse genome
by mRNA microarray (Supplementary Table 1). Unex-
pectedly, PPP1R3G, a predicted glycogen-targeting regu-
latory subunit of PP1 (13), was found to be highly
upregulated by fasting. By RT-PCR analysis, PPP1R3G was
expressed in many mouse tissues with a relatively high
level in liver, brain, lung, white adipose, and adrenal gland
(Supplementary Fig. 1A). As conﬁrmed by real-time RT-
PCR, PPP1R3G mRNA level was increased to ;12-fold and
35-fold in the liver after fasting for 6 and 12 h, respectively
(Fig. 1A). As a positive control, FGF21, which was
reported to be highly induced by fasting (24), was also el-
evated in our experiment (Fig. 1A). The protein level of
PPP1R3G was upregulated consistently by fasting in the
mouse liver (Fig. 1B) using an antibody generated in our
laboratory (Supplementary Fig. 1B and C). However, none
of the other three glycogen-related tissues, including brain,
white adipose, and skeletal muscle, had an induction of
PPP1R3G on fasting at the mRNA and protein levels (Fig.
1C, Supplementary Fig. 1D). PPP1R3G mRNA level was
quickly reduced after refeeding, reaching the prefasting
level after 2-h feeding (Fig. 1D). PPP1R3G protein was also
signiﬁcantly downregulated after refeeding (Fig. 1E). Col-
lectively, these data demonstrate that PPP1R3G is a cyclic
gene that changes along with the fasting–feeding cycle in
the mouse liver.
To identify the molecular mechanism that underlies the
regulation of PPP1R3G expression, we analyzed the ef-
fects of three major signals/hormones—glucagon, dexa-
methasone, and insulin—that have been shown by others to
regulate other fasting-related gene expression (25). In pri-
mary mouse hepatocytes, treatment of glucagon or dexa-
methasone alone could not signiﬁcantly elevate PPP1R3G at
both protein and mRNA levels (Fig. 1F and G). However,
when the cells were treated with these two factors together,
PPP1R3G was signiﬁcantly elevated at both protein and
mRNA levels (Fig. 1F and G). We next analyzed the activity
of a putative PPP1R3G promoter that contained a 2-kb
fragment in the 59 region upstream of PPP1R3G coding
region. In concert with the change at the protein and mRNA
levels, the PPP1R3G promoter activity was also signiﬁ-
cantly induced by dexamethasone and glucagon (Fig. 1I).
We found that PPP1R3G mRNA level and PPP1R3G pro-
moter activity were both reduced by insulin (Fig. 1H and J),
indicating that insulin signaling likely plays a role to turn off
PPP1R3G expression during refeeding.
Interaction of PPP1R3G with the catalytic subunit of
PP1. To conﬁrm whether PPP1R3G is indeed a glycogen-
related regulatory subunit of PP1, we ﬁrst investigated
whether PPP1R3G and PP1c were colocalized in the cell.
When the catalytic subunit of PP1 (the a isoform of
PP1c, the same for other exper i m e n t su s e di nF i g .2 )
was expressed alone, it was localized in the cytoplasm and
nuclei (Fig. 2A), consistent with a previous report (26).
However, when coexpressed with PPP1R3G, the cytoplasmic
mice were serum-starved for 10 h and then treated with 100 nmol/L glucagon or 1 mmol/L dexamethasone (Dex) for 12-h reagents as indicated for
12 h. The cell lysate was used in immunoblotting with the antibodies as indicated. G and H: Effect of glucagon, Dex, and insulin on PPP1R3G mRNA
level. Primary hepatocytes isolated from overnight-fasted mice were serum-starved for 10 h, treated with 100 nmol/L glucagon, 1 mmol/L Dex, or
100 nmol/L insulin as indicated for 12 h, followed by RT-qPCR. The fold change of PPP1R3G mRNA in the control group is set to 1. Data are shown
as mean 6 SD. *P < 0.05 in comparison with control group. I and J: Effect of glucagon, Dex, and insulin on PPP1R3G promoter activity. HepG2 cells
were transiently transfected with a PPP1R3G promoter luciferase reporter, serum-starved for 24 h, and then treated the reagents as in G for 12 h,
followed by luciferase assay. A renilla luciferase was cotransfected and used a reference control. Data are shown as mean 6 SD. *P < 0.05 and
***P < 0.001 compared with the untreated control. WAT, white adipose tissue.
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diabetes.diabetesjournals.org DIABETES, VOL. 60, MAY 2011 1437FIG. 2. Interaction of PPP1R3G with PP1c. A: PPP1R3G colocalizes with PP1c in the cytoplasm. Hela cells were transfected with Myc-PP1c alone
(top) or together with Flag-tagged PPP1R3G (bottom), followed by immunostaining and confocal analysis. Arrows indicate apparent colocalization
of PPP1R3G with PP1c. B: Endogenous PPP1R3G colocalizes with endogenous PP1c in the cytoplasm. Primary hepatocytes isolated from overnight-
fasted mice were used in immunostaining with the antibodies as indicated. Arrows indicate apparent colocalization of PPP1R3G with PP1c.
C: Interaction of PPP1R3G with PP1c as analyzed by GST pull-down assay. HEK293T cells were transiently transfected with Myc-tagged PP1c.
Twenty-four hours after transfection, cell lysate was incubated with GST proteins as indicated (top, Coomassie-stained gel), and the GST pull-
down product was used in immunoblotting (bottom). D: In vivo interaction of overexpressed PPP1R3G with PP1c. HEK293T cells were transiently
transfected with Flag-tagged PPP1R3G, Flag-tagged PPP1R3C, and Myc-tagged PP1c as indicated. Twenty-four hours after transfection, cell lysate
was used in immunoprecipitation (IP) and immunoblotting (IB) with the antibodies as indicated. E: In vitro interaction of PPP1R3G with PP1c.
Puriﬁed GST, GST-PPP1R3G, and His-PP1c (top, Coomassie-stained gel) were incubated as indicated, followed by GST pull-down and immuno-
blotting (bottom). F: Interaction of endogenous PPP1R3G with PP1c. Male C57BL/6 J mice at 8 weeks of age were killed in the feeding state or
after 12 h fasting. Liver protein was used in IB and IP. G: PPP1R3G is localized at the GEPs. HepG2 cells were transfected using the plasmids as
indicated. Twenty-four hours after transfection, the cells were homogenized and post-nuclear supernatant (PNS) was used in fractionation and IB
with an anti-Flag antibody. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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increased with a profound colocalization with PPP1R3G
(Fig. 2A). Endogenous PP1c and endogenous PPP1R3G
also had a profound cytoplasmic colocalization in primary
hepatocytes isolated from overnight-fasted mouse (Fig. 2B).
We used GST pull-down and coimmunoprecipitation
assays to analyze the interaction between the two proteins.
We found that the puriﬁed PPP1R3G GST fusion protein
could pull down PP1c in vitro (Fig. 2C). At the in vivo level,
these two proteins could also interact with each other in
a coimmunoprecipitation assay when they were coex-
pressed in HEK293T cells (Fig. 2D). As a positive control,
a known PP1 regulatory subunit, PPP1R3C (27), could also
interact with PP1c in the assay (Fig. 2D). Next, we ex-
plored whether the interaction is direct. We found that the
puriﬁed His-tagged PP1c protein was able to interact with
the puriﬁed PPP1R3G GST fusion protein in vitro (Fig. 2E).
At the animal level, the interaction of endogenous PPP1R3G
with endogenous PP1c in the liver of fasted mice was con-
ﬁrmed (Fig. 2F). In addition, the b isoform of PP1c was also
able to colocalize with PPP1R3G (Supplementary Fig. 2A)
and interact with PPP1R3G (Supplementary Fig. 2B and C).
To determine whether PPP1R3G is localized in the
glycogen-enriched pellet (GEP) fraction within the cell, we
fractionated PPP1R3G-transfected HepG2 cells by ultracen-
trifugation to obtain cytosolic and GEP fractions from post-
nuclear supernatant (28). PPP1R3G could be found in both
post-nuclear supernatant and GEP fractions (Fig. 2G), and
deletion of the predicted glycogen-binding motif led to
complete loss of GEP localization of PPP1R3G (Fig. 2G).
Furthermore, PPP1R3G could be detected in the supernatant
fraction after GEP fractions were treated with a-amylase
and sedimentation, further indicating glycogen association
of PPP1R3G (Supplementary Fig. 2D).
PPP1R3G stimulates glycogen synthesis in hepatocytes.
We next investigated the functional role of PPP1R3G in
glycogen synthesis. We constructed an adenovirus that
could overexpress PPP1R3G in mouse hepatocytes (Fig. 3A).
In vivo staining of glycogen in the primary hepatocytes and
HepG2 cells revealed that the cells with high expression of
PPP1R3G were associated with an increase of glycogen
content (Supplementary Fig. 3A and B). Direct measure-
ment of glycogen also demonstrated that PPP1R3G dose-
dependently increased the glycogen content in primary
hepatocytes (Fig. 3B). However, when the predicted gly-
cogen binding motif of PPP1R3G was deleted, the glycogen-
stimulating effect was completely abrogated (Supplementary
Fig. 3B and C).
Although overexpression of PPP1R3G itself was able to
elevate glycogen content in the absence of glucose in the
cultured cells (Fig. 3C), PPP1R3G-induced elevation of
glycogen synthesis was more effective with increasing the
level of glucose than the cells without PPP1R3G over-
expression (Fig. 3C), indicating that PPP1R3G-regulated
glycogenesis is dependent on available glucose substrate.
On the other hand, it has been proposed that glycogen-
targeting subunits of PP1 are involved in insulin regulation
of glycogen synthesis (29,30). We found that insulin could
increase glycogenesis in primary hepatocytes with or
without PPP1R3G overexpression (Fig. 3D). Meanwhile,
forskolin could reduce glycogen content in the presence of
overexpressed PPP1R3G (Fig. 3E). To further conﬁrm that
PPP1R3G is able to elevate glycogenesis, we used small
interfering RNA strategy to silence the expression of en-
dogenous PPP1R3G. Two of three shRNA sequences could
signiﬁcantly downregulate PPP1R3G expression at both
the mRNA level (Fig. 3F) and protein level (Fig. 3G). Con-
sistently, these two shRNA sequences reduced glycogen
content in primary hepatocytes (Fig. 3H). We also analyzed
glucose dependence of PPP1R3G shRNA (#962) on glyco-
genesis and found that PPP1R3G knockdown could reduce
glycogen content at various glucose concentrations (Fig. 3I).
Collectively, our data indicate that PPP1R3G is a regulatory
subunit of PP1 to facilitate stimulation of glycogen synthesis
in hepatocytes.
In vivo function of PPP1R3G on glycogen synthesis
and blood glucose homeostasis. We next analyzed the in
vivo function of PPP1R3G on the regulation of glycogen
synthesis and blood glucose homeostasis. We ﬁrst used
recombinant adenovirus to deliver PPP1R3G-expressing
plasmid to the mouse liver. Previous studies have shown
that intravenous administration of adenoviral vectors in
mice almost exclusively targets the transgene to the liver
(31). C57BL/6 J mice were injected with the control or
PPP1R3G-expressing adenovirus. Evaluation of amino-
transferases in the serum indicates that the PPP1R3G-
expressing adenovirus did not cause apparent functional
damage to the liver (Supplementary Fig. 4A).
By immunoblotting assay and real-time RT-PCR, we
conﬁrmed that the PPP1R3G-expressing adenovirus was
able to drive abundant expression of PPP1R3G in the
mouse liver (Fig. 4A and B). The PPP1R3G mRNA level
was elevated by the adenovirus to ;12-fold (Fig. 4B), com-
parable to the level induced by fasting (Fig. 1A). Consistent
with the observation with cultured hepatocytes, the liver
glycogen content of mice infected with PPP1R3G-expressing
adenovirus was signiﬁcantly elevated, reaching to approxi-
mately threefold higher than in control animals (Fig. 4C). We
next performed glucose tolerance tests with the animals.
PPP1R3G overexpression led to a decrease in fasting blood
glucose level and an increase in glucose clearance rate
(Fig. 4D), with the area under curve (AUC) of glucose tol-
erance test reducing by ;20% (Fig. 4E). However, insulin
tolerance test revealed no difference between the two
groups of mice (Fig. 4F), indicating that insulin sensitivity
is not altered by PPP1R3G overexpression in vivo. Col-
lectively, these data suggest that overexpressed PPP1R3G
could increase clearance of blood glucose likely by in-
creasing conversion of blood glucose into liver glycogen.
To support our hypothesis that fasting-induced PPP1R3G
is involved in postprandial blood glucose homeostasis,
we injected the mice with recombinant adenovirus that
contains shRNA speciﬁc for PPP1R3G, and the adeno-
virus did not cause apparent functional damage to the
liver (Supplementary Fig. 4). When PPP1R3G was silenced
in the liver, the fasting-induced PPP1R3G expression was
largely abrogated (Fig. 5A). After 12-h fasting, the mice
infected with PPP1R3G shRNA adenovirus had less
hepatic glycogen content than the control mice (Fig. 5B).
Refeeding for 1 h increased the hepatic glycogen content,
and such increase was signiﬁcantly attenuated when
PPP1R3G was downregulated (Fig. 5B). Most important,
the postprandial blood glucose clearance rate was altered
when PPP1R3G expression was silenced. The glucose
tolerance test revealed that the glucose clearance rate
was signiﬁcantly decreased in PPP1R3G-downregulated
mice in comparison with the control animals (Fig. 5C),
with AUC increasing by ;50% (Fig. 5D). However, insulin
sensitivity did not seem to be affected by downregulation
of PPP1R3G (Fig. 5E).
To provide further evidence that PPP1R3G is directly
involved in postprandial hepatic glycogenesis, we analyzed
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using
3H-labeled glucose as a tracer. Mice injected with
control or PPP1R3G-shRNA adenovirus were fasted for
12 h, followed by intraperitoneal injection of glucose
containing a trace amount of
3H -glucose. The mice were
killed in 1 h, and the isolated liver glycogen was subjected
to radioactivity measurement. As shown in Fig. 5F,t h e
amount of newly synthesized glycogen in the liver was re-
duced to ;50% by PPP1R3G knockdown. These data col-
lectively indicate that PPP1R3G is directly involved in
postprandial regulation of hepatic glycogenesis.
PPP1R3G modulates the activity of GS in coordi-
nation with the fasting–refeeding cycle. Because GS
and GP are two key enzymes modulated by PP1-mediated
dephosphorylation, we investigated whether PPP1R3G
could inﬂuence the activities of these two enzymes. When
PPP1R3G was overexpressed by adenovirus in the liver in
the fed state, GS activity was markedly elevated (Fig. 6A),
whereas GP activity was not affected (Fig. 6B). Because our
results indicate that PPP1R3G mainly acts on GS instead of
GP to regulate glycogenesis in the liver, we next focused on
analyzing the effect of PPP1R3G on GS activity during the
fasting–feeding cycle (Fig. 6C). In the fasting–feeding cycle,
GS activity deceased ;50% after fasting for 6 h and slightly
elevated to the unfasted level in 24 h. However, GS activity
was robustly increased on refeeding for 1 to 2 h and sub-
sequently declined to a very low level in 12 h. This phe-
nomenon is consistent with previous reports (32–34). We
FIG. 3. PPP1R3G stimulates glycogen synthesis in hepatocytes. A: Primary hepatocytes isolated from overnight-fasted mice were cultured over-
night and then treated with 25 multiplicity of infection (MOI) of Ad-GFP or Ad-PPP1R3G with a Flag tag at the N-terminus. Twenty-four hours
later, the cells were harvested for immunoblotting with antibodies as indicated. B: Primary hepatocytes isolated from overnight fasted mice were
infected with Ad-GFP or Ad-PPP1R3G at different MOI, followed by glycogen measurement. ***P < 0.001 in comparison with the Ad-GFP group.
C: The cells as in A were treated for 24 h with various glucose concentrations, followed by measurement of glycogen content. Data are shown as
mean 6 SD. **P < 0.01 as comparison between the two groups. D and E: The cells as in A were treated with 100 nmol/L insulin (for D)o r2 5mmol/L
forskolin (for E) for 24 h, followed by measurement of glycogen content. Data are shown as mean 6 SD. **P < 0.01 and ***P < 0.001 as comparison
between the treated and untreated groups. F: Hepatocytes isolated from overnight-fasted mice were cultured overnight and then treated with
25 MOI of Ad-shRNA as indicated. Cells were harvested 72 h later and analyzed by RT-qPCR. The fold change of PPP1R3G mRNA in Ad-Scrambled
shRNA group is set to 1. **P < 0.01 in comparison with the Ad-Scrambled shRNA group. G: Cell lysate from hepatocytes of G was used in im-
munoblotting with the antibodies as indicated. H: Cells as in G were used to measure glycogen content. ***P < 0.001 as compared with the
scrambled shRNA group. I: Primary hepatocytes isolated from overnight-fasted mice were cultured overnight and then treated with 25 MOI of
adenovirus as indicated. Forty-eight hours later, the cells were treated at various glucose concentrations for 24 h, followed by measurement of
glycogen content. Data are shown as mean 6 SD. *P < 0.05 and **P < 0.01 compared between the two groups.
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GS activity during the fasting–feeding cycle (Fig. 6C). We
found that the major effect of PPP1R3G knockdown is to
reduce GS activity around the fasting–refeeding transition.
During constant feeding and at early fasting or refeeding for
12 h, PPP1R3G knockdown only slightly reduced GS ac-
tivity. However, the GS activity was decreased to .40% in
the liver at fasting for 24 h and at refeeding for 1 to 2 h when
PPP1R3G was silenced. Accordingly, we found that the
phosphorylation level of GS at Ser641 in mouse livers was
very high during fasting and robustly reduced by refeeding
for 1 to 2 h (Supplementary Fig. 5), consistent with the
observation that GS activity was robustly stimulated by
refeeding (Fig. 6C). Furthermore, GS phosphorylation at
Ser641 was elevated by PPP1R3G knockdown during re-
feeding (Supplementary Fig. 5), consistent with the ﬁnding
that GS activity was reduced by PPP1R3G knockdown (Fig.
6C). Collectively, these data indicate that PPP1R3G mainly
functions during the period of fasting–refeeding transition
to regulate GS activity.
It is noteworthy that PPP1R3G is not the only glycogen-
targeting regulatory subunit of PP1 to regulate hepatic gly-
cogenesis. In addition to PPP1R3G, other glycogen-targeting
regulatory subunits of PP1, such as PPP1R3B, 3C, 3D, and
3E, are also expressed in the liver (13,27,35,36). In the
fed state, GL/PPP1R3B accounts for ;60% of GS phos-
phatase activity, and the PPP1R3C, 3D, and 3E account
for the remaining activity (13,37). To investigate how
these glycogen-targeting regulatory subunits orchestrate
to control hepatic glycogenesis, we analyzed the expres-
sion patterns of PPP1R3B, 3C, 3D, 3E, and 3G at different
times during fasting and refeeding (Fig. 6D). The mRNA
of PPP1R3A and PPP1R3F was hardly detectible in the
liver in our experiment (data not shown). Fasting for 24 h
could reduce the mRNA levels of PPP1R3B, 3C, and 3D,
whereas refeeding for 1 h signiﬁcantly elevated the mRNA
levels of these three subunits. The mRNA level of PPP1R3E
seemed to be unaffected by fasting and refeeding. In con-
trast, the expression of PPP1R3G was markedly stimulated
by fasting and rapidly reduced by refeeding. Taken together,
these data indicate that the expression pattern of PPP1R3G
differs from other glycogen-targeting subunits during the
fasting–feeding cycle.
DISCUSSION
So far there are seven glycogen regulatory subunits
(G subunits) of PP1 in mammals, PPP1R3A to PPP1R3G
(11,13). Phylogenetic tree analysis reveals that although all
seven human subunits and their rodent orthologs possess
known or putative PP1-interacting and glycogen-binding
domains, none of the subunits shares more than 40% amino
acid identity, suggesting that each subunit may serve a
nonredundant function in mammals (13). In this study, we
demonstrate that PPP1R3G is indeed a glycogen-targeting
regulatory subunit of PP1. At the cellular level, PPP1R3G is
associated with glycogen pellet, interacts with the catalytic
subunit of PP1, and regulates GS activity. At the animal
level, PPP1R3G is able to regulate glycogen synthesis in
the liver and modulate blood glucose homeostasis. Fasting
glucose level is reduced when PPP1R3G is overexpressed in
the liver. On the other hand, hepatic silencing of PPP1R3G
FIG. 4. PPP1R3G overexpression accelerates postprandial blood glucose clearance in the mouse. A: Overexpression of PPP1R3G in the mouse liver.
Male C57BL/6 J mice at 8 weeks of age were infected with adenovirus Ad-GFP or Ad-PPP1R3G (containing a Flag tag at N-terminus) via tail-vein
injection. At 9 days post-infection, animals were killed in the fed state. The livers were used in immunoblotting with antibodies as indicated. B:
PPP1R3G mRNA level in the liver was measured by RT-qPCR (n=6 mice/group) from the samples in A. Data are shown as mean 6 SD. ***P < 0.001
between the two groups. C: Liver glycogen content from samples in A were measured (n=8 for Ad-GFP and n=9 for Ad-PPP1R3G). ***P < 0.001 as
compared between the two groups. D–F: Glucose tolerance test (for D) and insulin tolerance test (for F) were performed at 4 days post-infection
(n=7 for Ad-GFP and n=8 for Ad-PPP1R3G). Mice were fasted for 4 h before glucose injection or insulin injection. Bar graph (E) represents the
AUC calculated from the glucose tolerance test. Data are shown as mean 6 SD. *P < 0.05, **P < 0.01, and ***P < 0.001 between the two groups
of mice.
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down postprandial clearance of blood glucose. Collectively,
our data reveal for the ﬁrst time that PPP1R3G is a func-
tional regulatory subunit of PP1 and plays a role in regu-
lating GS activity, hepatic glycogenesis, and postprandial
blood glucose homeostasis.
One of the most intriguing ﬁndings of this study is that
PPP1R3G is involved in the regulation of hepatic glyco-
genesis in a manner coupled to the fasting–feeding cycle
and distinct from other G subunits, especially GL/PPP1R3B,
a major protein that regulates liver glycogen metabolism. It
was originally reported in the early 1970s that liver GSP is
inhibited by GPa (38), explaining why GS becomes in-
hibited while GP is activated. It was later found that glu-
cose binds to GPa and promotes its dephosphorylation
and inactivation, thereby terminating the inhibition on GSP
by GPa so that glycogen can be resynthesized when blood
glucose is high after a meal (8). In the mid-1980s it became
clear that a form of PP1 was the major hepatic GSP in the
fed state and that this enzyme was inhibited allosterically
by GPa (39–41). The liver GSP in the fed state was later
puriﬁed and shown to be a complex of GL/PPP1R3B with
PP1 (42). The allosteric binding site for GPa was found to
be located on the GL/PPPR3B subunit, and not the PP1
catalytic subunit (42), and the GPa-binding site was located
at the extreme C-terminus of GL/PPPR3B (43,44). Mice that
expressed GL/PPP1R3B(Y284F) mutant that could not by
inhibited by GPa consistently showed enhanced activation
of hepatic GS and conversion of blood glucose into hepatic
glycogen (16). This information has been exploited to
FIG. 5. PPP1R3G knockdown slows down postprandial blood glucose clearance in the mouse. A: Knockdown of PPP1R3G in the mouse liver. Male
C57BL/6 J mice at 8 weeks of age were infected with shRNA adenovirus as indicated via tail-vein injection. At 15 days post-infection, animals were
killed in the fasted state (overnight fasting). Liver proteins were used in immunoblotting with the antibodies as indicated. B: Liver glycogen
content was measured from mice as in A after fasting and feeding for the time as indicated. Data are shown as mean 6 SD. ***P < 0.001 between
groups as indicated. C–E: Glucose tolerance test (for C) and insulin tolerance test (for E) were performed at 4 days post-infection (n=6 for Ad-
Scrambled-shRNA and n=8 for Ad-PPP1R3G-shRNA). Mice were fasted for 12 h before the test. AUC (for D) was calculated from the glucose
tolerance test. Data are shown as mean 6 SD. *P < 0.05, **P < 0.01, and ***P < 0.001 between the two groups. F: Postprandial newly synthesized
liver glycogen using D-[3-
3H]glucose as a tracer was measured with mice at 7 days post-infection (n=8 for both Ad-Scrambled-shRNA and Ad-
PPP1R3G-shRNA groups). Mice were fasted for 12 h and intraperitoneally injected with glucose (2 g/kg body wt) containing trace amount of
D-[3-
3H]glucose. Mice were killed in 1 h, and liver glycogen was isolated and used in scintillation counting. Data are shown as mean 6 SE. **P <
0.01 between the two groups.
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1442 DIABETES, VOL. 60, MAY 2011 diabetes.diabetesjournals.orgFIG. 6. PPP1R3G modulates the activity of GS in coordination with the fasting–refeeding cycle. A and B: Liver GS and GP activities were measured
from the samples as in Fig. 4A.D a t aa r es h o w na sm e a n6 SD. ***P < 0.001 between the two groups. C: Male C57BL/6 J mice at 8 weeks of age were
infected with shRNA adenovirus as indicated via tail-vein injection. Seven days after infection, animals were killed in constant feeding state, after
fasting, or after refeeding for the time as indicated (n=4 or 5 mice/group). Liver GS activity is shown as mean 6 SE. *P < 0.05 and **P < 0.01. The
numbers above the bars of Ad-scrambled-shRNA group mark the actual GS activity. The numbers above the bars of Ad-PPP1R3G group represent the
percentage decrease of GS activity in this group in comparison with the control group, respectively. D:E x p r e s s i o np a t t e r n so fP P P 1 R 3 Ga n do t h e r
glycogen-targeting regulatory subunits of PP1 in the liver during fasting and refeeding. The liver samples of mice (n=4 mice/group) with fasting and
refeeding for different amounts of time were used to determine the mRNA levels of PPP1R3B, 3C, 3D, 3E, and 3G by RT-qPCR. Data are shown as
mean 6 SD. *P < 0.05 and **P < 0.01 compared with the unfasted group. E:S i m p l i ﬁed model to depict the expression patterns of glycogen-targeting
regulatory subunits of PP1 in the liver during the fasting–feeding cycle and their roles in regulating GS activity and hepatic glycogenesis in mouse.
Fasting increases PPP1R3G expression but decreases the expression of other glycogen-targeting regulatory subunits of PP1, including PPP1R3B, 3C,
and 3D, whereas refeeding has an opposite effect. The combined effects of PPP1R3G together with other glycogen-targeting regulatory subunits of PP1
determine how these subunits contribute to GS activity and liver glycogenesis at different phases of the fasting–feeding cycle. Because of its unique
expression pattern, PPP1R3G plays a major role in regulating hepatic glycogenesis during the fasting–feeding transition. For simplicity purposes, the
expression pattern of PPP1R3E is not included because its expression level is not changed during the fasting–feeding cycle in the liver.
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action between GPa and GL/PPP1R3B to enhance the
conversion of blood glucose to hepatic glycogen (45). It is
noteworthy that inhibition by GPa is the unique feature of
GL/PPP1R3B not shared by any other G subunit, including
PPP1R3G. We propose that the lack of a GPa binding site
in PPP1R3G, and therefore presumably the lack of allo-
steric inhibition of the PP1-PPP1R3G complex by GPa,
comprises a crucial difference from the PP1-PPP1R3B
complex. Such a difference may explain why PPP1R3G is
needed at the fasting–feeding transition. During starva-
tion, when the glucagon/insulin ratio is high, GP would be
expected to be largely in the active form. At the early
stage of the fasting–feeding transition when GPa has not
been inactivated, one would not want GPa to inhibit GSP
activity; otherwise, GS activity would not be activated
efﬁciently and the glucose could not be rapidly used to
replenish hepatic glycogen after a meal. At the early
stages of the fasting–feeding transition, the expression
of PPP1R3G reaches its maximum while GL/PPP1R3B ex-
pression is minimal (Fig. 6D). Thus, PP1-PPP1R3G complex
may function as the major GSP at this time. In the normally
fed state, the PP1-PPP1R3B complex may replace the PP1-
PPP1R3G complex as the major GSP so that the important
allosteric regulation by GPa can be introduced. Consistent
with our model, it was found that GL/PPP1R3B accounts for
;60% of GSP activity in the fed state (13,37). Because of the
functional and expressional difference between PPP1R3G
and other G subunits, especially GL/PPP1R3B in the liver, it
is expected that the major physiologic mission of PPP1R3G
is to ensure rapid activation of GS and rapid glycogen syn-
thesis in the liver shortly after a meal, subsequently con-
tributing to postprandial glucose clearance (Fig. 6E).
When feeding triggers stimulation of GS activity via
different means, such as a rapid increase of blood glucose
and insulin levels, insulin-mediated phosphorylation and
inactivation of GSK-3, translocation of GS to the cellular
periphery, conversion of intracellular glucose to G6P, and
portal signals (2,5,10,11), the PPP1R3G-mediated GS ac-
tivity would rapidly lead to hepatic glycogenesis and re-
moval of postprandial blood glucose. In a simplistic way,
and as judged by the increase of AUC in the glucose tol-
erance test in PPP1R3G knockdown mice (Fig. 5D), the
reduction of postprandial newly synthesized liver glycogen
(Fig. 5F), and the decrease of GS activity by these mice
shortly after refeeding (Fig. 6C), it can be estimated that at
least 50% of the postprandial hepatic glycogen synthesis
and the reduction in blood glucose are mediated by a
PPP1R3G-mediated mechanism. In humans, hepatic gly-
cogenesis is reduced in diabetic patients, and genetic
variations of genes involved in glycogen metabolism have
been found in diabetic patients (46–48). In mice, although
Suzuki et al. (14) reported that deletion of GM/PPP1R3A
had no obvious defects, other reports indicate that de-
letion of GM/PPP1R3A leads to increased weight gain,
obesity, glucose intolerance, and insulin-resistance (15,49).
Hepatic expression of a C-terminus–truncated form of
GM/PPP1R3A in streptozotocin-induced diabetic rats can
reverse hyperglycemia and hyperphagia (50). Mice that
expressed the GL/PPP1R3B(Y284F) mutant that could not
be inhibited by GPa had an enhanced activation of hepatic
GS activity and improved glucose tolerance (16). In addi-
tion, heterozygous deletion of PTG/PPP1R3C in mice led to
glucose intolerance, hyperinsulinemia, and insulin resis-
tance with aging (17). Therefore, the next challenge will be
to determine whether alteration of PPP1R3G is associated
with insulin resistance and type 2 diabetes and whether
modulation of PPP1R3G can serve as a new strategy to
improve glucose metabolism.
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